EPHX2 and metabolic syndrome: We report that chronic oral treatment with t-AUCB (~1 mg/kg/day), a potent sEH inhibitor [22], alleviated the symptoms of metabolic syndrome in vivo including glucose, insulin and lipid abnormalities, changes in pancreatic structure, increased systolic blood pressure, and cardiovascular and liver structural and functional abnormalities induced by chronic high-carbohydrate high-fat feeding in rats.